EGFR and lung carcinoma: For example, EGFR mutations in exons 18-21 are common druggable targets in lung cancer 34; although it is designated as a PAT in other tumors, mutations at this specific locus are absent in BTC, suggesting a potential risk of narrowing the genome-driven targeted therapy coverage population when only accurate mutated loci are considered.